{"id":"https://openalex.org/W2907050147","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.e19070","title":"Preliminary results of a phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology (NSCLC-NS) with disease progression after a bevacizumab (bev) containing therapy.","display_name":"Preliminary results of a phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology (NSCLC-NS) with disease progression after a bevacizumab (bev) containing therapy.","publication_year":2014,"publication_date":"2014-05-20","ids":{"openalex":"https://openalex.org/W2907050147","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.e19070","mag":"2907050147"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2014.32.15_suppl.e19070","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.e19070","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2014.32.15_suppl.e19070","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5014554706","display_name":"Thomas E. Stinchcombe","orcid":"https://orcid.org/0000-0002-3595-8011","observed_orcids":["https://orcid.org/0000-0002-3595-8011"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas E. Stinchcombe","raw_affiliation_strings":["The University of North Carolina at Chapel Hill, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of North Carolina at Chapel Hill, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022384270","display_name":"Jared M. Weiss","orcid":"https://orcid.org/0000-0003-2961-4447","observed_orcids":["https://orcid.org/0000-0003-2961-4447"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jared Weiss","raw_affiliation_strings":["Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082389042","display_name":"Liza Cosca Villaruz","orcid":"https://orcid.org/0000-0001-7456-523X","observed_orcids":["https://orcid.org/0000-0001-7456-523X"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Liza Cosca Villaruz","raw_affiliation_strings":["University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025478600","display_name":"Anastasia Ivanova","orcid":"https://orcid.org/0000-0003-4321-2073","observed_orcids":["https://orcid.org/0000-0003-4321-2073"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anastasia Ivanova","raw_affiliation_strings":["Department of Biostatistics, The University of North Carolina at Chapel Hil, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistics, The University of North Carolina at Chapel Hil, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059915005","display_name":"Juneko E. Grilley\u2010Olson","orcid":"https://orcid.org/0000-0002-1896-7020","observed_orcids":["https://orcid.org/0000-0002-1896-7020"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Juneko E. Grilley-Olson","raw_affiliation_strings":["Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028994853","display_name":"Nirav Dhruva","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nirav Suresh Dhruva","raw_affiliation_strings":["Rex Hematology Oncology Associates, Raleigh, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rex Hematology Oncology Associates, Raleigh, NC","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5078629724","display_name":"Mark A. Socinski","orcid":"https://orcid.org/0000-0003-2915-9325","observed_orcids":["https://orcid.org/0000-0003-2915-9325","https://orcid.org/0000-0002-8213-0137"]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark A. Socinski","raw_affiliation_strings":["University of Pittsburgh, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh, Pittsburgh, PA","institution_ids":["https://openalex.org/I170201317"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"32","issue":"15_suppl","first_page":"e19070","last_page":"e19070"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.8871999979019165,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.8871999979019165,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.09319999814033508,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.009499999694526196,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pazopanib","display_name":"pazopanib","score":0.996999979019165},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9670000076293945},{"id":"https://openalex.org/keywords/non-squamous-histology","display_name":"non-squamous histology","score":0.9330000281333923},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.8640000224113464},{"id":"https://openalex.org/keywords/bevacizumab-resistance","display_name":"bevacizumab resistance","score":0.8140000104904175},{"id":"https://openalex.org/keywords/vegfr-tyrosine-kinase-inhibitors","display_name":"VEGFR inhibitors","score":0.8740000128746033},{"id":"https://openalex.org/keywords/anti-angiogenic-therapy","display_name":"anti-angiogenic therapy","score":0.8939999938011169},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.8759999871253967},{"id":"https://openalex.org/keywords/disease-control-rate","display_name":"disease control rate","score":0.9190000295639038},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6690000295639038},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6970000267028809},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.574999988079071},{"id":"https://openalex.org/keywords/hepatotoxicity","display_name":"hepatotoxicity","score":0.49000000953674316},{"id":"https://openalex.org/keywords/anorexia","display_name":"anorexia","score":0.4399999976158142},{"id":"https://openalex.org/keywords/fatigue","display_name":"fatigue","score":0.5649999976158142},{"id":"https://openalex.org/keywords/mucositis","display_name":"mucositis","score":0.8270000219345093}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.931338369846344},{"id":"https://openalex.org/C2778439243","wikidata":"https://www.wikidata.org/wiki/Q7157043","display_name":"Pazopanib","level":4,"score":0.7444509863853455},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.7262043952941895},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6698310971260071},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6265923976898193},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.5940327644348145},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5189263820648193},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5016541481018066},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.47109541296958923},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3827795684337616},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3395736813545227},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.338169127702713},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.33396124839782715},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.29737967252731323},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2746490240097046},{"id":"https://openalex.org/C2779490328","wikidata":"https://www.wikidata.org/wiki/Q417542","display_name":"Sunitinib","level":3,"score":0.09439551830291748}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2014.32.15_suppl.e19070","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.e19070","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2014.32.15_suppl.e19070","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9922999739646912}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1975814972","https://openalex.org/W2597944602","https://openalex.org/W2256279578","https://openalex.org/W2075176584","https://openalex.org/W2963756957","https://openalex.org/W1810708577","https://openalex.org/W2031791697","https://openalex.org/W2259076612","https://openalex.org/W2533509293","https://openalex.org/W2054945564"],"abstract_inverted_index":{"e19070":[0],"Background:":[1],"Bev-containing":[2],"therapy":[3,79,205],"is":[4],"a":[5,31,76,155],"standard":[6],"for":[7,107,140,230,240,265],"stage":[8,67,196],"IIIB/IV":[9],"NSCLC-NS.":[10],"Mechanisms":[11],"of":[12,27,129,157,280],"resistance":[13],"to":[14,55,65,72,85,152,154,166,207,212],"bev":[15,50],"are":[16],"unclear":[17],"and":[18,84,172,192,216,234,256,275],"may":[19,51],"involve":[20],"increase":[21,288],"VEGF":[22,28,33],"signaling":[23],"or":[24,69,101,104],"increased":[25],"activation":[26],"receptors.":[29],"Pazopanib,":[30],"multi-targeted":[32],"receptor":[34],"tyrosine":[35],"kinase,":[36],"has":[37,315],"activity":[38,317],"in":[39,318,320],"advanced":[40],"NSCLC.":[41],"Patients":[42],"who":[43,322],"have":[44,66,73,86,323],"previously":[45],"tolerated":[46],"and/or":[47],"benefited":[48],"from":[49,57],"be":[52,138,261],"more":[53],"likely":[54],"benefit":[56],"second-line":[58],"anti-angiogenic":[59],"therapy.":[60],"Methods:":[61],"Pts":[62,111],"were":[63,112,176,190,246,268],"required":[64],"IIIB":[68],"IV":[70,197],"NSCLC-NS,":[71],"progressed":[74],"on":[75,178],"bevacizumab":[77],"containing":[78],"<":[80,231],"9":[81],"weeks":[82],"prior,":[83],"adequate":[87],"organ":[88],"function.":[89],"The":[90,248,263],"primary":[91],"end-point":[92],"was":[93,124,163,183,251],"disease":[94,106,133,145,229,239,269,325],"control":[95,146],"rate":[96],"(DCR),":[97],"defined":[98],"as":[99],"partial":[100],"complete":[102],"responses,":[103],"stable":[105,228,238],"\u2265":[108,241],"12":[109,232,242],"weeks.":[110,243],"assessed":[113],"radiographically":[114],"every":[115],"2":[116,209,235],"cycles":[117],"(6":[118],"weeks).":[119],"A":[120],"Simon":[121],"2-stage":[122],"design":[123],"used;":[125],"if":[126,142],"\u2264":[127],"4":[128,203,225],"17":[130],"pts":[131,175,189,194,221],"experienced":[132,144,324],"control,":[134],"the":[135,147,179,200],"trial":[136,148],"would":[137,149],"stopped":[139],"futility;":[141],"\u22655":[143],"then":[150],"proceed":[151],"enroll":[153],"total":[156],"36":[158],"pts.":[159],"An":[160],"unplanned":[161],"analysis":[162],"performed":[164],"due":[165,211],"slow":[167],"accrual.":[168],"Results:":[169],"Between":[170],"12/2010":[171],"11/2013,":[173],"15":[174,201],"treated":[177],"trial.":[180],"Median":[181],"age":[182],"61":[184],"yrs":[185],"(range":[186],"39-74),":[187],"8":[188],"women,":[191],"all":[193],"had":[195,222,227,237],"disease.":[198],"Of":[199],"pts,":[202],"discontinued":[204],"prior":[206],"cycle":[208],"evaluation":[210],"adverse":[213,272],"events":[214,273],"(n=3)":[215],"medical":[217,276],"illness":[218,277],"(n=1),":[219,292,298,300,307],"5":[220],"progressive":[223],"disease,":[224],"patients":[226,236,321],"weeks,":[233],"No":[244],"responses":[245],"observed.":[247],"DCR":[249],"observed":[250,286],"13%":[252],"(2/15).":[253],"Progression-free":[254],"survival":[255,258],"overall":[257],"data":[259,312],"will":[260],"presented.":[262],"reasons":[264],"treatment":[266,283],"discontinuation":[267],"progression":[270,326],"(n=9),":[271],"(n=4),":[274],"(n=2).":[278],"Episodes":[279],"grade":[281],"3":[282],"related":[284],"toxicities":[285],"include":[287],"ALT":[289],"(n=2),":[290,302],"AST":[291],"anorexia":[293],"(n=3),":[294,296,304],"fatigue":[295],"hypertension":[297],"infection":[299],"mucositis":[301],"nausea":[303],"pericardial":[305],"effusion":[306],"vomiting":[308],"(n=1).":[309],"Conclusions:":[310],"Preliminary":[311],"suggest":[313],"pazopanib":[314],"limited":[316],"NSCLC-NS":[319],"after":[327],"bevacizumab.":[328]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2019-01-11T00:00:00"}